New drug combo cuts chemo nausea in half for gynecologic cancer patients
NCT ID NCT06007586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug aprepitant to standard anti-nausea medicine helps women with gynecologic cancers (like ovarian or cervical cancer) who are getting chemotherapy. 143 women took part. The goal was to see if the extra drug could better prevent nausea and vomiting after chemo. The results show that the three-drug combo works better than the standard two-drug approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dengfeng Wang
Chengdu, Sichua, 610041, China
-
Sichuan Cancer Hospital
Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- What raises endometrial cancer risk in black women? a study digs in
- Can a new PET tracer light up hidden cancers?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?